Skip to main content
Faith Nathan, MD, Oncology, Moorestown, NJ


Oncology Moorestown, NJ

Genitourinary Oncology, Hematologic Oncology, Thoracic Cancer


Dr. Nathan is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Connect with other colleagues in the same hospital or clinic
  • Search all U.S. specialist profiles and refer a patient
  • Read the latest clinical news and earn CME/CEU credits

See Dr. Nathan's full profile

Already have an account?


  • Dr. Faith Nathan is an oncologist in Moorestown, NJ. She received her medical degree from Rutgers New Jersey Medical School and has been in practice 30 years. She specializes in genitourinary oncology, hematologic oncology, and thoracic cancer and is experienced in immunotherapy, urologic oncology, thoracic oncology, clinical trials as topic, and lung neoplasms. She has more than 40 publications and over 500 citings. She retired in July 2023.

Education & Training

  • Drexel University College of Medicine/Hahnemann University Hospital
    Drexel University College of Medicine/Hahnemann University HospitalFellowship, Hematology and Medical Oncology, 1989 - 1992
  • Cooper Medical School of Rowan University/Cooper University Hospital
    Cooper Medical School of Rowan University/Cooper University HospitalResidency, Internal Medicine, 1987 - 1989
  • Rutgers New Jersey Medical School
    Rutgers New Jersey Medical SchoolClass of 1986

Certifications & Licensure

  • NJ State Medical License
    NJ State Medical License 1987 - 2023
  • PA State Medical License
    PA State Medical License 1988 - 2006
  • American Board of Internal Medicine Internal Medicine

Clinical Trials

Publications & Presentations


Journal Articles

  • Pain in castration-resistant prostate cancer with bone metastases: a qualitative study  
    Gater A, Abetz-Webb L, Battersby C, Parasuraman B, McIntosh S, Nathan F, Piault EC, Health & Quality of Life Outcomes, 2011
  • Differences in treatment patterns among patients with castration-resistant prostate cancer treated by oncologists versus urologists in a US managed care population  
    Engel-Nitz NM, Alemayehu B, Parry D, Nathan F, Cancer management and research, 2011
  • A phase II, randomized, multicenter study to assess the efficacy, safety, and tolerability of zibotentan (ZD4054) in combination with pemetrexed in patients with advan...  
    Chouaid C, Nathan F, Pemberton K, Morris T, Cancer Chemother Pharmacol, 2011
  • Join now to see all

Professional Memberships